Please login to the form below

Not currently logged in
Email:
Password:

Novartis recalls several OTC products in US

Batches of Excedrin, NoDoz, Bufferin and Gas-X Prevention voluntarily withdrawn and operations suspended at Nebraska manufacturing plant

Novartis has recalled batches of four over-the-counter products in the US following complaints of chipped and broken pills as well as well as inconsistent clearance practices for bottle packaging at a manufacturing plant.

Painkiller Excedrin and caffeine tablet NoDoz, with expiry dates of December 20, 2014, have been withdrawn, along with aspirin Bufferin and Gas-X Prevention products that have expiry dates of December 20, 2013.

Speaking to Bloomberg, Novartis' Julie Masow said the number of products involved in the recall was still unknown.

Operations and shipments at the Novartis Consumer Health's facility in Lincoln, Nebraska, which manufactured the products have also been suspended to 'accelerate maintenance and other improvement activities at the site'.

A potential mix up in tablets due to the plant's unreliable practices "could not be ruled out", the company said.

The recalls and required improvements to its Lincoln facility will cost Novartis $120m, which the company expects to book as a one-off charge in its 2011 fourth quarter figures.

It is not known when the plant will resume full operations, or whether the problems will have any further financial impact on the pharmaceutical company.

Joseph Jimenez, CEO of Novartis, said: "We are committed to a single quality standard for the entire Novartis Group and we are making the necessary investments and committing the right resources to ensure these are implemented across our entire network.”

No related adverse events have been reported as of yet, and Novartis said the recalls were a 'precautionary measure'.

9th January 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Litmus MME

LITMUS places the development of strong physician relationships at the centre of every program and has established a new standard...

Latest intelligence

Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...
Russian innovation at the crossroads
Despite improvements, investors face rising risks...